image dons

je fais un don

Supraventricular arrhythmias more common than thought after percutaneous PFO closure

PFO - Stroke - AF

La Grande Journée du Coeur (22 juin 2022)
Les présentations sont en ligne

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Programme en ligne - Inscriptions ouvertes !

Article publié dans JACC: Cardiovasc Interv. Aug 22, 2022. Epub DOI: 10.1016/j.jcin.2022.07.044

Auteurs : Guedeney P, Laredo M, Zeitouni M, Hauguel-Moreau M, Wallet T, Elegamandji B, Alamowitch S, Crozier S, Sabben C, Deltour S, Obadia M, Benyounes N, Collet JP, Rouanet S, Hammoudi N, Silvain J, Montalescot G.

Article disponible ici


Background :

Randomized studies have reported low rates of atrial fibrillation (AF) after patent foramen ovale (PFO) closure (<6%) but have relied on patient-reported symptomatic episodes, so the true incidence and timing of AF after PFO closure remain unknown.

Objectives :

The aim of this study was to prospectively determine the incidence, timing, and determinants of supraventricular arrhythmia following PFO closure on the basis of loop recorder monitoring.

Methods :

Cardiac monitoring was proposed to all patients after PFO closure from June 2018 to October 2021 at a single center by means of implantable loop recorder monitoring in patients considered at higher risk for AF (age ≥ 55 years, associated cardiovascular risk factors, prior palpitations, or documented supraventricular ectopic activity) or 4-week external loop recorder monitoring in other patients. The primary endpoint was the incidence of AF, atrial flutter, or supraventricular tachycardia lasting >30 seconds within 28 days of the procedure. Determinants of the primary endpoint were assessed using a stepwise logistic regression model.

Results :

A total of 225 patients were included. The primary endpoint occurred in 47 patients (20.9%), including 13 (9.9%) and 24 (28.9%) among patients monitored with external loop recorders and implantable loop recorders, respectively. Overall, the median delay from procedure to arrhythmia was 14.0 days (IQR, 6.5-19.0 days), and one-half of these patients reported symptomatic episodes. Determinants of the primary endpoint were older age (adjusted OR: 1.67 per 10-year increase; 95% CI: 1.18-2.36), device left disc diameter ≥25 mm (adjusted OR: 2.67; 95% CI: 1.19-5.98) and male sex (adjusted OR: 4.78; 95% CI: 1.96-11.66).

Conclusions :

Using loop recorder monitoring for ≥28 days, supraventricular arrhythmia was diagnosed in 1 in 5 patients, with a median delay of 14 days, suggesting that this postprocedural event has so far been underestimated.

Autres actualités

+

04/10/2022


Pathologies cardiaques de la femme

20e Colloquium de l'Institut (Modérateurs : Dr S. Manzo-Silberman, Pr G. Montalescot). Découvrez le programme et réserve...
+

04/10/2022


Etude ADVOR

Acétazolamide - Décompensation cardiaque
+

27/09/2022


Essai INVICTUS

Rivaroxaban - AVK - FA rhumatismale